奥当卡替涂层促进种植体骨结合:一项临床前研究
本研究将组织蛋白酶K抑制剂奥当卡替(ODN)分散于模拟体液中,涂层于双酸蚀钛种植体(SLA),植入72只雄性Wistar大鼠胫骨,评估第15天和第40天的骨结合。结果显示,第15天时ODN涂层组去除扭矩、局部骨体积及推定骨-种植体接触均显著优于对照,组织形态计量学显示新骨面积比呈非显著增加趋势,第40天该趋势持续。提示局部递送组织蛋白酶K抑制剂可支持早期骨结合。
要点
- ODN涂层种植体第15天去除扭矩显著高于对照(p=0.017)
- 第15天局部骨体积和推定骨-种植体接触亦显著增加
- 组织形态计量学新骨面积比增加未达统计学显著(p=0.102)
核心结论
- 局部递送组织蛋白酶K抑制剂奥当卡替可支持啮齿类异位植入模型的早期骨结合阶段。
研究设计与样本
- 临床前动物实验:72只雄性Wistar大鼠胫骨植入双酸蚀钛种植体(SLA),有无ODN涂层比较。
- 评估时间点为第15天和第40天,方法包括生物力学测试、显微计算机断层扫描和组织形态计量学分析。
主要发现
- 第15天去除扭矩从2.5 Ncm(1.5-4.4)增至3.9 Ncm(1.7-7.6),p=0.017。
- 第15天局部骨体积从24.4%(13.86-32.45)增至32.8%(19.7-39.4),p=0.003。
- 第15天推定骨-种植体接触从34.38%(27.0-50.0)增至43.33%(31.6-54.2),p=0.035。
- 第15天组织形态计量学新骨面积比从34.78%(18.9-43.7)增至41.10%(23.5-54.0),p=0.102。
- 上述趋势在第40天骨结合后持续。
临床怎么用
- 提示ODN作为种植体局部涂层可能促进早期骨结合,但尚需临床研究验证。
局限性
- 研究为啮齿类动物异位植入模型,结果外推至人类需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Odanacatib (ODN), a cathepsin K inhibitor, is a drug that reduces bone resorption while preserving bone formation. ODN was initially developed for the treatment of postmenopausal osteoporosis, but further development as a systemic medication has been discontinued. Here, we propose ODN as a topical treatment, the coating of dental implants, to achieve an anabolic shift of early osseointegration. MATERIAL AND METHODS: To this aim, we have coated double acid etching titanium implants (SLA) with and without ODN dispersed in a simulated body fluid (SBF). The implants were inserted into the tibia of 72 male Wistar rats and osseointegration was studied on Days 15 and 40. Biomechanical testing, micro-computed microtomography, and histomorphometric analyses were performed. RESULTS: Biomechanical testing reveals that after 15 days of healing, removal torque increased from 2.5 Ncm (1.5-4.4) to 3.9 Ncm (1.7-7.6) when comparing SBF alone with SBF containing ODN, respectively (p = 0.017). Consistently, micro-computed microtomography indicated that local bone volume increased from 24.4% (13.86-32.45) to 32.8% (19.7-39.4), respectively (p = 0.003). The same was true for presumed bone-to-implant contact, which was 34.38% (27.0-50.0) and 43.33% (31.6-54.2), respectively (p = 0.035). Histomorphometric analyses confirmed that the new bone area per total area increased from 34.78% (18.9-43.7) to 41.10% (23.5-54.0), respectively (p = 0.102). This trend proceeds after 40 days of osseointegration. DISCUSSION: These findings suggest that topical delivery of a cathepsin K inhibitor can support the early osseointegration phase in an ectopic rodent implantation model.
引用
- Dos Santos Sanches N, Marchiolli CL, Cervantes LCC, et al. Odanacatib Coating Supports Osseointegration of Implants: A Preclinical Study. Clin Oral Implants Res. 2025. PMID: 40908780. doi:10.1111/clr.70038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。